Exploiting the Vulnerabilities of High-Grade Serous Ovarian

Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.

Related Keywords

Massachusetts , United States , Boston , Dana Farber Cancer Institute , Colombo , Western , Sri Lanka , American , Joycef Liu , , End Results Program , Zentalis Pharmaceuticals , Astrazeneca , Women Health , Harvard Medical School , Division Of Gynecologic Oncology , American Society Of Clinical Oncology Annual Meeting , National Cancer Institute Surveillance , Gynecologic Oncology , Displays Preliminary Efficacy , Clinical Oncology Annual Meeting , Gynecologic Oncology Annual Meeting , Cancer Institute Surveillance , End Results , Accessed May , Intj Mol ,